{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:26:47Z","timestamp":1786768007608,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.msard.2021.103146","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T18:15:38Z","timestamp":1626891338000},"page":"103146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings"],"prefix":"10.1016","volume":"55","author":[{"given":"Carolina M","family":"Rimkus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Andreoli","family":"Schoeps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus","family":"Boaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Filipe","family":"Godoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira Luisa","family":"Apostolos-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Luisa","family":"Calich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Tavares","family":"Lucato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Sastre-Garriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia da Costa","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.msard.2021.103146_bib0002","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1177\/1352458519895445","article-title":"Iatrogenic demyelinating disorders: New insights, new culprits","volume":"26","author":"Abboud","year":"2020","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2021.103146_bib0003","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.103146_bib0004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol Ther"},{"issue":"2","key":"10.1016\/j.msard.2021.103146_bib0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1352458515623862","article-title":"MS arising during Tocilizumab therapy for rheumatoid arthritis","volume":"22","author":"Beauchemin","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103146_bib0006","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2015.03.022","article-title":"Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation","volume":"282","author":"Berger","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2021.103146_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2006.058404","article-title":"Natalizumab and progressive multifocal leucoencephalopathy","author":"Berger","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.msard.2021.103146_bib0008","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/ard.2009.111500","article-title":"Demyelinating events in rheumatoid arthritis after drug exposures","volume":"69","author":"Bernatsky","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.msard.2021.103146_bib0009","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrneurol.2011.1","article-title":"Monoclonal antibody therapy-associated neurological disorders","volume":"7","author":"Bosch","year":"2011","journal-title":"Nature reviews. Neurology"},{"issue":"5","key":"10.1016\/j.msard.2021.103146_bib0010","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"16","key":"10.1016\/j.msard.2021.103146_bib0011","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","article-title":"CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment","volume":"86","author":"Cao","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2021.103146_bib0012","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jat\/bkr025","article-title":"Determination of phenyltetrahydroimidazothiazole enantiomers (Levamisole\/Dexamisole) in illicit cocaine seizures and in the urine of cocaine abusers via chiral capillary gas chromatography-flame-ionization detection: clinical and forensic perspectives","volume":"36","author":"Casale","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.msard.2021.103146_bib0013","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbi.2015.06.019","article-title":"Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound","volume":"50","author":"Cavone","year":"2015","journal-title":"Brain Behav. Immun."},{"issue":"2","key":"10.1016\/j.msard.2021.103146_bib0014","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2021.103146_bib0015","first-page":"S164","article-title":"The role of natalizumab in the treatment of multiple sclerosis","volume":"16","author":"Coyle","year":"2010","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.msard.2021.103146_bib0016","article-title":"Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation","author":"Croteau","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2021.103146_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.msard.2021.103146_bib0018","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1177\/1352458519852100","article-title":"A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence","volume":"25","author":"Diebold","year":"2019","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2021.103146_bib0019","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"1997","journal-title":"J. Immunother."},{"issue":"5","key":"10.1016\/j.msard.2021.103146_bib0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"8","key":"10.1016\/j.msard.2021.103146_bib0021","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1177\/1352458518772913","article-title":"Rebound disease in multiple sclerosis","volume":"24","author":"Giacomini","year":"2018","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2021.103146_bib0022","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00415-017-8509-9","article-title":"Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases","volume":"264","author":"Gieselbach","year":"2017","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2021.103146_bib0023","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1177\/1352458518763095","article-title":"Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation","volume":"24","author":"Giordana","year":"2018","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2021.103146_bib0024","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10792-007-9038-9","article-title":"Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia","volume":"27","author":"Govind Babu","year":"2007","journal-title":"Int. Ophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2021.103146_bib0025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1148\/rg.274065103","article-title":"Radiology of recreational drug abuse","volume":"27","author":"Hagan","year":"2007","journal-title":"Radiographics"},{"issue":"11","key":"10.1016\/j.msard.2021.103146_bib0026","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jamaneurol.2016.3202","article-title":"Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation-Reply","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.103146_bib0027","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-\u03b1: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.msard.2021.103146_bib0028","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2011.05.005","article-title":"Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy","volume":"142","author":"Ingwersen","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.msard.2021.103146_bib0029","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P2.2-093","article-title":"Nilotinib-associated Demyelinating Disease (P2.2-093)","volume":"92","author":"Judge","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2021.103146_bib0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.autrev.2013.09.002","article-title":"Demyelination and other neurological adverse events after anti-TNF therapy","volume":"13","author":"Kaltsonoudis","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.msard.2021.103146_bib0031","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS Demyelination with TNF-\u03b1 Blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"2468","key":"10.1016\/j.msard.2021.103146_bib0032","article-title":"Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.msard.2021.103146_bib0033","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1352458519828601","article-title":"Iatrogenic CNS demyelination in the era of modern biologics","volume":"25","author":"Kumar","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2021.103146_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.103146_bib0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458516641775","article-title":"Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal","volume":"23","author":"Larochelle","year":"2017","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2021.103146_bib0036","doi-asserted-by":"crossref","first-page":"e82796","DOI":"10.1371\/journal.pone.0082796","article-title":"Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment","volume":"8","author":"Linker","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.msard.2021.103146_bib0037","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1212\/WNL.0000000000001150","article-title":"Levamisole-induced leukoencephalopathy mimicking Bal\u00f3 disease","volume":"84","author":"Long","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2021.103146_bib0038","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/exnr.1997.6598","article-title":"5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus","volume":"147","author":"Lucchinetti","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.msard.2021.103146_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102568","article-title":"CNS demyelination during tofacitinib therapy: First report","volume":"46","author":"Massoud","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.msard.2021.103146_bib0040","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-15-0141","article-title":"Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma","volume":"3","author":"Maurice","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.msard.2021.103146_bib0041","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/cen3.12239","article-title":"Bevacizumab is safe in acute relapses of neuromyelitis optica","volume":"6","author":"Mealy","year":"2015","journal-title":"Clinical & experimental neuroimmunology"},{"key":"10.1016\/j.msard.2021.103146_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00005","article-title":"Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis","volume":"9","author":"Mills","year":"2018","journal-title":"Frontiers in neurology"},{"key":"10.1016\/j.msard.2021.103146_bib0043","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents \u2013 Comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"issue":"25","key":"10.1016\/j.msard.2021.103146_bib0044","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103146_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.538695","article-title":"Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature","volume":"11","author":"Oliveira","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"11","key":"10.1016\/j.msard.2021.103146_bib0046","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.msard.2021.103146_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101496","article-title":"Tumefactive inflammatory leukoencephalopathy in cocaine users: Report of three cases","volume":"38","author":"Pessini","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"10.1016\/j.msard.2021.103146_bib0048","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s40425-019-0818-3","article-title":"Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient","volume":"7","author":"Pillonel","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"19","key":"10.1016\/j.msard.2021.103146_bib0049","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000435293.34351.11","article-title":"Tumefactive MS lesions under fingolimod: A case report and literature review","volume":"81","author":"Pilz","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103146_bib0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ctrv.2017.12.008","article-title":"Checkpoint inhibitors in breast cancer \u2013 Current status","volume":"63","author":"Polk","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.msard.2021.103146_bib0051","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuroscience.2015.06.038","article-title":"TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects","volume":"302","author":"Probert","year":"2015","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.msard.2021.103146_bib0052","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nature reviews. Disease primers"},{"issue":"12","key":"10.1016\/j.msard.2021.103146_bib0053","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2016-315106.154","article-title":"Cns Demyelination In Patients On Nilotinib Treatment For Cml","volume":"87","author":"Rekhi","year":"2016","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"6382","key":"10.1016\/j.msard.2021.103146_bib0054","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.msard.2021.103146_bib0055","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1590\/2237-6089-2017-0143","article-title":"Adulterants in crack cocaine in Brazil","volume":"41","author":"Ribeiro","year":"2019","journal-title":"Trends Psychiatry Psychother"},{"key":"10.1016\/j.msard.2021.103146_bib0056","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212173","article-title":"Tumefactive demyelination presenting during bevacizumab treatment","author":"Rice","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"2","key":"10.1016\/j.msard.2021.103146_bib0057","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.sult.2013.09.005","article-title":"Toxic leukoencephalopathies, including drug, medication, environmental, and radiation-induced encephalopathic syndromes","volume":"35","author":"Rimkus Cde","year":"2014","journal-title":"Semin. Ultrasound CT MR"},{"issue":"9","key":"10.1016\/j.msard.2021.103146_bib0058","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/1352458519892914","article-title":"CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases","volume":"26","author":"Rotstein","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103146_bib0059","series-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","author":"Ryerson","year":"2019"},{"key":"10.1016\/j.msard.2021.103146_bib0060","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fimmu.2018.00444","article-title":"Tumor Necrosis Factor \u03b1 and Regulatory T Cells in","volume":"9","author":"Salomon","year":"2018","journal-title":"Oncoimmunology. Front Immunol"},{"issue":"1","key":"10.1016\/j.msard.2021.103146_bib0061","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1186\/1756-0500-7-641","article-title":"Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case report","volume":"7","author":"Sato","year":"2014","journal-title":"BMC Research Notes"},{"issue":"5","key":"10.1016\/j.msard.2021.103146_bib0062","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.msard.2021.103146_bib0063","article-title":"Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod","volume":"10","author":"Song","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2021.103146_bib0064","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"Sorensen","year":"2012","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2021.103146_bib0065","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2021.103146_bib81","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS Results of a randomized, placebo-controlled multicenter study","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103146_bib0066","series-title":"Susceptibility-Weighted MR Imaging Hypointense Rim in Progressive Multifocal Leukoencephalopathy: The End Point of Neuroinflammation and a Potential Outcome Predictor","author":"Thurnher","year":"2019"},{"issue":"1","key":"10.1016\/j.msard.2021.103146_bib0067","first-page":"53","article-title":"Treatment of multiple sclerosis - success from bench to bedside. Nature reviews","volume":"15","author":"Tintore","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2021.103146_bib0068","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"The Lancet Neurology"},{"issue":"6","key":"10.1016\/j.msard.2021.103146_bib0069","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103146_bib0070","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","article-title":"Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients","volume":"70","author":"Vellinga","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2021.103146_bib0071","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/1352458514549401","article-title":"Significant clinical worsening after natalizumab withdrawal: Predictive factors","volume":"21","author":"Vidal-Jordana","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103146_bib0072","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jneuroim.2017.01.018","article-title":"Confirmed case of levamisole-associated multifocal inflammatory leukoencephalopathy in a cocaine user","volume":"305","author":"Vitt","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2021.103146_bib0073","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-015-0467-1","article-title":"Multifocal leukoencephalopathy in cocaine users: a report of two cases and review of the literature","volume":"15","author":"Vosoughi","year":"2015","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.msard.2021.103146_bib0074","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WCO.0000000000000099","article-title":"Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI","volume":"27","author":"Wattjes","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2021.103146_bib0075","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.msard.2021.103146_bib0076","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1552-6569.2008.00344.x","article-title":"Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patients","volume":"19","author":"Xu","year":"2009","journal-title":"Journal of neuroimaging : official journal of the American Society of Neuroimaging"},{"key":"10.1016\/j.msard.2021.103146_bib0077","article-title":"Role of TNF\u2013TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"issue":"1-2","key":"10.1016\/j.msard.2021.103146_bib0078","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3121\/cmr.2019.1417","article-title":"Nivolumab-Associated Acute Demyelinating Encephalitis: A Case Report and Literature Review","volume":"17","author":"Zafar","year":"2019","journal-title":"Clinical medicine & research"},{"issue":"5","key":"10.1016\/j.msard.2021.103146_bib0079","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"The Lancet Neurology"},{"issue":"5","key":"10.1016\/j.msard.2021.103146_bib0080","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1524-4741.2012.01293.x","article-title":"Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer","volume":"18","author":"Zhou","year":"2012","journal-title":"Breast J."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:32:40Z","timestamp":1786764760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821004132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":80,"alternative-id":["S2211034821004132"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103146","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103146"}}